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First human administration of a new chemical entity (NCE)
constitutes a critical step in drug development. The primary
objective of such a study is the assessment of the short-
term safety and tolerability of single and multiple doses of
the NCE in healthy volunteers. Secondary objectives are to
obtain preliminary data on the pharmacokinetics and phar-
macodynamics using surrogate or biomarkers of the bene-
ficial as well as the adverse effects of the drug. Interpreta-
tion of safety data should be cautious and mainly based on
comparisons with placebo. A special focus should be made
on the assessment of adverse events, liver enzymes, and
cardiac repolarization. Well-designed, first-time-to-man
studies should determine the safety of the NCE in humans
and predict the dose range that may be used to safely and
accurately conduct further clinical trials in the target patient
population based on safety data (maximum tolerated
dose), pharmacodynamics (minimum active dose, duration
of action, and dosage regimen), and pharmacokinetics
(dosage regimen).
he path of a new drug from concept to medica-
tion may be divided into two phases, namely
drug discovery and drug development.Clinical pharma-
cology, also known as phase 1 or human pharmacology,
constitutes one of the most critical steps in drug devel-
opment,as it forms the link between drug discovery and
preclinical and clinical drug development,and produces
the necessary basis for the confirmatory phase 2 and 3
clinical trials of a new chemical entity (NCE) in patients
with the target indication.Clinical pharmacology consti-
tutes an exploratory stage of drug development during
which essential information should be provided about
the safety, the pharmacokinetics (quantitative descrip-
tion of the disposition of a drug in the body or a body
compartment over time:“what does the body do to the
drug?”), and the pharmacodynamics (quantitative
description of drug effects, activity, or toxicity:“what
does the drug do to the body?”).
Clinical pharmacology starts with the first-time-to-man
(FTTM) administration of an NCE and lasts throughout
drug development.Assessment of the short-term safety
and tolerability of single and multiple doses of an NCE
in healthy volunteers,whatever the route of administra-
tion,is the main objective of the FTTM studies.In addi-
tion, preliminary pharmacokinetics and pharmacody-
namics (ie, surrogate or biomarkers of expected
pharmacological activity and/or unwanted side effects)
should be secondary objectives of these studies.
Study design
No specific guidelines exist; only three gold standards
apply: the study should be double-blind and placebo-
controlled,and safety is paramount.One dose level may
be evaluated in small subgroups of 3 to 5 subjects (2 to
3 subgroups per dose level) and the dose must be
increased only after careful review of all the data avail-
able from the previous dose level. Indeed,“go/no go”
decisions about further drug development must be
made at all stages of the FTTM studies.These decisions
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Pharmacological aspectsdetermine the progression of the studies, firstly to the
next higher dose, then from the single- to the multiple-
dose study, and finally from one population (healthy
subjects) to another (“at-risk” population or patient
population).The aim is to define the maximum tolerat-
ed dose (MTD) in humans based on the evaluation of
adverse events (AEs), routine laboratory tests, vital
signs (temperature, respiratory rate, supine and stand-
ing blood pressure, and heart rate), and electrocardio-
grams (ECG).
1-3 A sequential parallel-group or a
crossover design may be used for single-dose studies.
Multiple-dose studies are done using a sequential par-
allel-group design with a duration of administration of
1 to 4 weeks, usually 2 weeks. Eight to 12 subjects are
usually included per dose level (6 to 9 subjects on active
treatment versus 2 to 3 subjects on placebo).
Both designs have pros and cons.The main advantages of
a sequential design are that a larger number of subjects
are exposed to the NCE and that naive subjects are
exposed at each dose level, and thus there are no con-
cerns about a possible carryover effect in pharmacoki-
netics and/or pharmacodynamics. No wash-out is
required,reducing the time factor.Modifying dose levels
or dosing occasions according to the results obtained at
lower doses is easy and allows flexibility; it has optimal
feasibility and no problems with drop outs.The disadvan-
tages of the sequential design are that there is no placebo
control for individual variations in the various parameters
assessed and that there is no measure of within-subject
variability and dose proportionality in pharmacokinetic
parameters.The main advantage of crossover studies is
that they have a better design for assessing any
dose–effect relationship; there is a placebo control for
individual variations and an enhanced statistical power.
However, there are many disadvantages: a smaller num-
ber of subjects are exposed;each subject is exposed more
than once with the possibility of a carryover effect (espe-
cially due to the limited knowledge available about the
compound at this stage of the development); and finally
replacement of possible drop-out subjects can turn into a
nightmare, prolonging the duration of the study and/or
leading to a loss of the increased statistical power if, for
any reason,subjects are not replaced.
Adverse events
The most usual ways of monitoring AEs include spon-
taneous reporting by the subject and the investigator’s
own observations. Occasionally, a symptom checklist
may be used; however this sometimes leads to an over-
estimation of the number of AEs.
In the field of central nervous system (CNS) drugs,it is
also possible to assess subjective effects on mood and
alertness by self-rating using either visual analogue
scales (VASs) or questionnaires. The two most fre-
quently used VASs are the Leeds Analogue Rating
Scales (LARS) and the Bond and Lader VAS.
4,5 The
LARS consists of eleven 10-cm long VASs on which
subjects compare their present feelings with their usual
status. Average scores for the three sedation scales,
“tiredness,”“drowsiness,” and “alertness,” are used to
measure perceived sedation.The Bond and Lader VAS
consists of sixteen 10-cm bipolar analogue scales with
two opposite mood-related adjectives at the end of the
scales.It refers to the subjects’ present feelings without
any reference to their usual status. Factorial analysis of
these scales yields three factors, alertness, contented-
ness,and calmness.
5
Sleep may also be assessed using VASs.The most fre-
quently used scale is the Leeds Sleep Evaluation Ques-
tionnaire (LSEQ).
6,7 It consists of ten 10-cm long scales.
It is completed by the subject about 30 minutes after
awakening and is used to rate subjective impressions of
the ease of getting to sleep, the quality of sleep, the
awakening from sleep, and behavior following waking
(early morning hangover).
Among the various questionnaires used to assess mood
and behavior, the Profile Of Mood Scale (POMS) and
Addiction Research Center Inventory (ARCI) are fre-
quently used.The POMS
8 is a 65-adjective checklist.Sub-
jects rate each item on a 5-point scale from 0 (“not at all”)
to 4 (“extremely”),and 7 scores are obtained:anger/hos-
tility, confusion/bewilderment, depression/dejection,
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Selected abbreviations and acronyms
AE adverse event
ALT alanine aminotransferase
AP alkaline phosphatase
AST aspartate aminotransferase
EMEA European Agency for the Evaluation of Medic-
inal Products 
FTTM first-time-to-man
NCE new chemical entity
VAS visual analogue scale205
fatigue, friendliness, tension/anxiety, and vigor. The
ARCI
9,10 consists of 49 true or false questions from which
were derived five major scores:the morphine–benzedrine
group (a measure of euphoria),the pentobarbital–chlor-
promazine–alcohol group (a measure of sedation), the
lysergic acid diethylamide (LSD) group (a measure of
dysphoria), and the benzedrine group and the ampheta-
mine-sensitive scales for stimulant effect.
Other specific scales or questionnaires may be used
depending on the drug evaluated and the dimension of
action being investigated: the Spielberger State/Trait
Anxiety Inventory
11 for anxiety; various questionnaires
to assess abuse liability of drugs
10-12;the Clinical Institute
Withdrawal Assessment-Benzodiazepine (CIWA-B)
13 to
assess and monitor benzodiazepine-like withdrawal; or
the Simpson-Angus and Barnes Akathisia scales to
assess the extrapyramidal side effects of neuroleptics.
VASs may also be used to assess nausea,pain,thirst,etc.
AE reporting is one of the most difficult tasks in clinical
trials.The interpretation may vary among investigators.
Training and clear explanations should be provided,
especially for AE coding,in order to standardize as much
as possible.As already mentioned, double-blind, place-
bo-controlled conditions are mandatory. Indeed, place-
bo may produce adverse events with an overall incidence
ranging from 7.4%
14 (24 studies conducted in the same
Clinical Pharmacology Unit in Europe and involving 430
subjects) to 19%
15 (109 studies outsourced to various
Clinical Pharmacology Units in Europe and involving
1228 subjects).The most frequently encountered AE
after placebo administration are headache (2% to 7%)
and drowsiness/asthenia (10%).This “nocebo” effect
emphasizes the need for placebo-controlled studies.
Liver tests
Hepatotoxicity is the leading reason for removal of an
NCE from the market or for discontinuation of drug
development.A recent study of agents approved and
subsequently banned because of safety concerns showed
that in 28% of cases (8 cases in this study),liver damage
was either the only reason (4 cases) or one of the rea-
sons (4 cases) for discontinuation.
16 Of 130 drugs with-
drawn from the market for safety reasons between 1964
and 1992, adverse effects on the liver were responsible
in 18% of cases.
17 Drug development of 29 out of 320
NCEs was terminated due to clinical toxicity, including
9 cases (31%) due to effects on the liver.
18 Information
from preclinical studies using cultured hepatocytes,
covalent binding in microsomes, etc, predicted possible
liver effects in some cases.
These data illustrate both the importance of detecting a
potential hepatotoxic effect of an NCE and the possi-
bility of false-negative results during preclinical and
clinical tests on hepatotoxicity.One of the key objectives
of phase 1 trials is to assess the safety of an NCE in
humans, and in particular to document the absence of
hepatotoxicity.
True liver tests are albumin, serum prothrombin time,
and/or partial thromboplastin time, but these are not
sensitive enough to detect early liver damage. Usual
screening for liver damage in clinical trials comprises
total bilirubin (TB), alanine aminotransferase (ALT or
serum glutamate pyruvate transaminase [SGPT]),aspar-
tate aminotransferase (AST or serum glutamate
oxaloacetate transaminase [SGOT]),and alkaline phos-
phatase (AP). Lactate dehydrogenase (LDH) is too
insensitive and too nonspecific, and gamma-glutamyl-
transferase (gamma-GT) is too nonspecific for moni-
toring liver damage. Increases in AP and gamma-GT
may be induced by drugs. Both are indicators of
cholestasis and are nonspecific.
It is also important to clearly define drug-induced liver
disorders.
19,20 Unless a liver biopsy has been performed,
the lesions should not be named according to the histo-
logical findings,eg,cirrhosis,chronic liver disease,hepat-
ic necrosis,or hepatitis.The preferred term is liver injury.
The term liver injury should be used if there is an
increase of over 2N (N representing the upper limit of
the normal range) in ALT or conjugated bilirubin or a
combined increase in AST,AP, and TB, provided one of
them is above 2N.No other biochemical test is specific to
liver disorder.Increases in ALT,AST,AP,or TB between
N and 2N indicate abnormality of liver tests, not liver
injury. Isolated increases in AST,AP, or TB even above
2N should be considered as a simple biochemical abnor-
mality and not necessarily a sign of liver injury.
There are three types of liver injury:hepatocellular liver
injury,characterized by an increase in ALT alone of over
2N or R>5 (R=ALT/AP,each measured as a multiple of
N);cholestatic liver injury,characterized by an increase
in AP alone of over 2N or R<2; and mixed liver injury,
characterized by an increase in both ALT (over 2N) and
AP,and 2<R<5.An acute liver injury corresponds to an
increase in liver test values over less than 3 months. In
contrast,a chronic liver injury is an increase in liver test
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values over more than 3 months. Severe liver injury
refers to the presence of,in order of increasing severity,
jaundice, prothrombin level below 50%, and hepatic
encephalopathy.
ALT is the most sensitive and the most specific routine
laboratory test available to detect early liver damage.
Thus, any elevation of ALT above the upper limit of
the laboratory should be considered and any signifi-
cant increase in ALT during the early phase, most
notably in repeated-dose studies in healthy volunteers,
may lead to discontinuation of development of a drug.
The value of 2N is often considered as a threshold to
define a potentially clinically significant abnormality
(PCSA). However,ALT elevation to levels above the
upper limit of normal range (ULN) has been observed
in healthy young subjects treated only with placebo
with a prevalence ranging from 12% to 22% in the lit-
erature (Table I).
21-23 This prevalence increases after
placebo treatment lasting more than 1 week. In a
recent review of data gathered from 152 hospitalized
healthy young male volunteers participating in ran-
domized, double-blind, placebo-controlled, 14-day,
ascending-multiple-dose safety studies,the prevalence
of ALT levels above ULN was 18.4%,with 13% having
an abnormality of liver tests (value between N and 2N)
and 5% a liver injury (value above 2N).Infectious dis-
ease (mononucleosis,toxoplasmosis,or viral infection)
may explain this elevation in a few subjects,but it gen-
erally remains unexplained. The usual causes of
increases in ALT and AST, such as physical activity
(30% to 40% increase in ALT and 30% to 70%
increase in AST associated with an increase in creatine
phosphokinase [CPK]),hypercaloric and hyperglucidic
diet (100% increase in ALT and AST),
24,25 excessive
consumption of alcohol (20% to 30% increase in ALT
and AST), and overweight (10% to 60% increase in
ALT and AST), can be ruled out. Indeed, overweight
subjects are excluded from participating in such stud-
ies and the restrictions during the study (alcohol intake
forbidden,standardized normal diet,and no strenuous
physical activities) are easy to control as the subjects
are hospitalized throughout the study.
The duration of hospitalization may have a major impact
on the prevalence of transaminase elevation on placebo,
since most cases occur during the second week of hospi-
talization. One factor may be an imbalance between
reduced physical activity and maintained caloric intake.
Kanamaru et al
26 reported ALT elevation in a group of
subjects who rested for 7 days, contrasting with an
absence of significant changes in a control group of sub-
jects who engaged in daily physical exercise. However,
other studies involving bed rest for a week or more
(space medicine, metabolic studies) did not report ALT
elevation.
27
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Author Population Number of Duration of Prevalence
studies administration
Wyld et al* 49 males 6 4–16 days 12.2% (n=6)
Kobayashi et al
21 104 males - 1–7 days 12.5% (n=13)
Merz et al
22 100 males 13 7–31 days 22% (n=22) 
(19–45 years)  (mean 14 days)
Merz et al
22 100 males 13 7–31 days 22% (n=22) 
(19–45 years)  (mean 14 days)
Rosenzweig et al
23 93 males 13 14 days 20.4% (n=19) 
(18–40 years)
French phase 1 club: increase in ALT levels after placebo (1996)**
Subjects Duration of  ALT<N 1N≤ ALT≤ 1.5N 1.5N≤ ALT≤ 2N 2N≤ ALT≤ 3N ALT>3N  Prevalence
exposed administration
78 males 7 days 75 1 2 0 0 3 (4.0%)
152 males 14 days 124 (81.6%) 14 (9.2%) 6 (3.9%) 6 (3.9%) 2 (1.3%) 28 (18.4%)
(18–40 years)
N = upper limit of the normal range
Table I. ALT increase above upper limit of normal range in healthy subjects treated with placebo. * Unpublished communication, 1991; 
** unpublished communication, 1996.207
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The composition of the diet may play a role. Porikos et
al
24 showed that a combination of excess calories and a
high sucrose intake was associated with enzyme eleva-
tion.The role of carbohydrates was further confirmed
by an 8-day, three-way, crossover study in 12 healthy
subjects comparing a high-fat diet (58% fat) providing
4500 kcal/day, a high-carbohydrate diet (32% sugar,
27% carbohydrates) providing 4400 kcal/day, and a
“healthy” diet providing 1900 kcal/day.Whereas liver
function tests remained normal in all the subjects on the
healthy and high-fat diets, significant increases in ALT
levels sometimes of more than 100% were observed in
5 of the 12 subjects on the high-carbohydrate diet. In
most phase 1 trials, the diet provides less than 2500
kcal/day with a reasonable proportion of carbohydrates,
but the carbohydrate intake was not always closely
maintained within predefined limits.
The identification of clinically significant abnormalities
of liver enzymes should be done on a case-by-case basis,
taking into account an absolute threshold, usually the
upper limit of the normal range (below this threshold,
any value would be considered as a spontaneous varia-
tion), and a variation from baseline exceeding sponta-
neous variation (for instance, a 50% increase in the
baseline value or an increase exceeding 20% of the
upper limit of the normal range).
28,29 Decision charts to
manage liver tests abnormalities have been determined
following consensus meetings (Figure 1)
30 and are help-
ful to the investigator because they define when a drug
should be discontinued (usually increase in ALT and/or
AST above 3N with CPK normal) and the procedures
to be followed to identify a possible cause other than the
investigational drug.They are also useful to the sponsor
as they standardize the procedure to be followed by the
various investigators.
Cardiac repolarization
QT interval prolongation is a serious drug safety issue
that should be properly addressed in drug development.
Class III antiarrhythmic agents, such as amiodarone,
sotalol, and bretylium, and class Ia antiarrhythmic
agents, such as quinidine, procainamide, and disopyra-
mide, are designed to intentionally prolong cardiac
repolarization. However, a number of drugs have been
shown to prolong cardiac repolarization unintentional-
ly to such a degree that potentially life-threatening ves-
ticular tachycardia called torsades de pointes may
Increase in aminotransferases
either ALT (SGPT) or AST (SGOT) and CPK normal
                    
Drug administration may be continued
Repeat the measurement
- every 48 h for the first week 
- then once weekly until return to normal 
  or at least 1 month after the end of the trial
≤ 3N >3N
≤ 3N
• Discontinue administration of the drug and check the result immediately.
• Inform the local monitor.
• Interview patient again about consumption of alcohol, drugs received 
    before and during the trial, and possible contamination by non-A, non-B
    virus in the last 6 months (blood or blood transfusion, travel to Africa, 
    Asia, intravenous drug addiction).
• Investigate for illness and/or hypotension and/or episode of arrhythmia
    in the previous 48 h.
• Freeze serum (5 mL x2).
• Perform the following examinations:
    - complete blood count including reticulocytes;
    - serum creatinine;
    - anti-HAV IgM, anti-HBc IgM, anti-HCV IgM, anti-CMV IgM;
    - specific serologic markers or recent infection with:
       * EBV, herpes viruses, and toxoplasmosis (depending on the clinical context),
       * Hepatobiliary ultrasonography.
• Monitor aminotransferases every 3 days for the first week then once weekly 
    until return to normal or for at least 3 months.
Figure 1. Increase in aminotransferase (expressed as a multiple
of the upper limit of normal range [N] for the labora-
tory performing the assay).
ALT: alanine aminotransferase; SGPT: serum glutamate pyru-
vate transaminase; AST: aspartate aminotransferase; SGOT:
serum glutamate oxaloacetate transaminase; CPK: creatine
phosphokinase; HAV: hepatitis A virus; IgM: immunoglobulin;
HBc: hepatitis B core; HCV: hepatitis C virus; CMV:
cytomegalovirus; EBV: Epstein-Barr virus.
Reproduced from reference 30: Benichou C. Management of
adverse events during clinical trial. In: Benichou C, ed. Adverse
Drug Reaction. A Practical Guide to Diagnosis and Treatment.
Chichester, UK: John Wiley and Sons Ltd; 1994:223-232.
Copyright © 1994, John Wiley and Sons.result.
31 Several drugs are known to delay repolariza-
tion and to be associated with a prolongation of QT
interval and possibly torsade de pointes: tricyclic anti-
depressants, antipsychotics (thioridazine, chlorpro-
mazine),antihistamines (terfenadine,astemizole),anti-
infectives (erythromycin, chloroquine, halofantrine),
and miscellaneous drugs (cisapride, terodiline,
furosemide, prednisolone, and beta-agonists).
32-34 Pro-
longation of cardiac repolarization is easily identified
using ECG. Increased QT intervals in a patient are
indicative of prolonged cardiac repolarization.Howev-
er,because the QT interval is dependent on heart rate,
it has to be corrected into a new variable independent
of heart rate, called the corrected QT interval (QTc).
Various equations have been proposed for this.The
most widely used is Bazett’s formula (QTc = QT/√ RR).
This formula gives an excellent correction for a heart
rate value of 60 bpm.However,it overestimates (under-
corrects) QTc at low heart rate and underestimates
(overcorrects) QTc at high heart rate values.
35 Frideri-
cia’s formula (QTc = QT/
3√ RR) seems to have better
predictive properties than Bazett’s formula.
36-38
In 1997, the European Agency for the Evaluation of
Medicinal products (EMEA) proposed a “points to
consider”document for the assessment of the potential
for QT interval prolongation by a noncardiovascular
medicinal product.
39 Several papers in the literature also
emphasize the need to assess cardiac repolarization.
40,41
During phase 1, ECGs are collected from healthy, nor-
mal subjects,usually males,several times before,during,
and after drug administration.The potential for QT
interval prolongation of a noncardiovascular NCE
should be assessed in a randomized, double-blind,
placebo-controlled study, and with a sufficient number
of doses to be able to characterize the dose–response
relationship,including doses sufficiently higher than the
proposed therapeutic dose to demonstrate a no-effect
outcome.The time course of ECG effects should be
evaluated according to the pharmacokinetic profile of
the parent compound, as well as its active (toxic)
metabolites if appropriate,after a single dose as well as
at steady-state plasma concentrations. This timing
should coincide with the expected Cmax of the NCE or
when the maximum concentration in the target cardiac
cell is expected.
The EMEA document also emphasized that, at pre-
sent, automatic readings from 12-lead ECGs are gen-
erally not considered sufficiently accurate and reliable.
Holter may be useful to assess the occurrence of
arrhythmia, but this is also inaccurate and not reliable
enough for QTc readings,as it does not correlate suffi-
ciently well with 12-lead ECG recorded at the same
time. Therefore, manual reading of QT intervals by
trained personnel is recommended.
Thus,according to the EMEA document,the QT inter-
val should be measured using standard 12-lead record-
ing (at 25 and 50 mm/s including a long lead II with at
least 10 QRS complexes) with manual reading. The
measurement of QT interval and QT dispersion should
be assessed as the mean of 3 to 5 beats. In general, the
U wave should not be included when the QT interval is
measured. Both mean change from baseline and raw
data should be adequately reported. Change in T-wave
morphology and/or the occurrence of a U wave consti-
tute important warning signs, which have the same sig-
nificance as prolongation of QTc.
Automatic ECG reading indeed yields more conserv-
ative results than manual reading. QTc interval calcu-
lated according to Bazett’s formula is on average 19
ms (range: -86 to +47 ms) shorter when measured
manually than when measured automatically by a
Marquette Mac 15 apparatus.
37 In a recent review of
866 ECGs recorded during a single-ascending-dose
FTTM study, the manual reading (average of 3 beats
measured in V2) of QTc interval calculated using
Bazett’s formula was 16 ms shorter (range: -77 to 105
ms) and the QTc interval calculated using Fridericia’s
formula 23 ms shorter (range: -65 to +121 ms) than
automatic measurement from a Marquette Mac 6
(Patat, unpublished data). Automatic QTc reading
may therefore be thus sufficient for the monitoring of
cardiac repolarization in real time in FTTM studies.
However,the individual values vary widely from -90 to
+100 ms and caution should be taken. However, auto-
matic reading is particularly unreliable when there are
difficulties in the measurement of the QT interval,
such as in cases of a flat, broad, or notched T wave, in
the presence of a U wave,when a P wave superimpos-
es the T wave,or when the downslope of the T wave is
distorted by noise. In such cases, QT should be
checked by manual reading.
Holter recording is even less accurate and produces
QTc values which may be over- or underestimated
depending on the ECG lead assessed.The measure-
ments of QTc from Holter were 24 ms shorter (range:
-100 to 55 ms) in V1 and 13 ms longer (range: -42 to 
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20862 ms) in V5 than QTc values from standard ECG when
comparing the same complexes (Christiansen et al,pre-
sented at the 5th International Congress of Ambulatory
Monitoring,1992).
QTc is always 20 to 30 ms longer in females than in
males,justifying different acceptable ranges (450 ms for
males and 470 ms for females) (Table II).
There is a diurnal variation of QTc interval.The QTc is
longer (about 19±7 ms) during sleep than during wak-
ing hours when calculated at a heart rate of 60 bpm in
15 normal subjects.This may be due to increased vagal
tone or sympathetic withdrawal.
46,47
The QTc interval may be longer in some patient popu-
lations. QTc is longer in cardiac patients (mean QTc is
407 vs 417 ms in matched age and gender controls;
QTc>440 ms in 25% [7 out of 28] of patients vs 3% 
[1 out of 28] of controls).
48 QTc is longer in cirrhotic
patients (440 vs 394 ms in matched controls) and
increases with Child-Pugh Score (QTc>440 ms in 50%
of cirrhotic patients [44 out of 94 patients], 25%, 52%,
and 63% patients for Child-Pugh A, B, and C, respec-
tively,and 5% of controls [2 out of 37]).
49
When examining data for individual patients, it is
important to separate random,nonsystematic variabil-
ity from variability caused by the drug. In order to be
able to interpret any QTc change from baseline, it is
mandatory to know the within-subject variability over
the time of ECG.This may be studied by looking at
QTc changes observed in placebo-treated subjects.
Pratt et al
48 showed that 50% (14 out of 28) of healthy
male subjects had at least 1 of the 40 ECGs recorded
during the 6-day period of the study with a QTc value
above a threshold of 440 ms. In the same study, 71%
(20 out of 28) of cardiac patients had at least one QTc
value above 440 ms when receiving placebo treat-
ment.
48The average QTc fluctuation or variability over
24 hours in normal men, measured as the difference
between the shortest and the longest QTc value
recorded, was 56±15 ms
48 or 59±12 ms.
50 Individual
healthy male subjects (n=20) had a wide range of QTc
fluctuations over 24 hours which averaged 76±19 ms
(range:35–108 ms) when QTc was measured by Holter
recording.
51 Among these subjects, the QTc interval
increased to over 440 ms in 11 of the 20 subjects (55%)
during the 24-hour monitoring period.It even exceed-
ed 500 ms in 1 of the 20 subjects.
51When looking at the
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Males Females Both
genders
Moss,
42 1993
Mean ± SD (ms) 410±10 420±20
Range (ms) 380–440 370–480 
n 222 198
Rassmussen et al,
43 1991
Mean all day (ms) 392 421
Range (ms) 346–438 376–467 
n 30 30
Gunput et al,
44 1995
Range (ms) 378–441 
n 641 343 984
Patat et al, 1998*
Mean ± SD (ms) 404±14
Range (ms) 360–440
n 280
Adamson et al,
45 1998
Mean ± SD (ms) 389±20 405±21
n 701 290
Table II. QTc interval (Bazett’s formula) of 12-lead ECG in healthy subjects. * Unpublished data, 1998.fluctuations observed during the first 12 hours of dos-
ing of healthy young subjects hospitalized in a clinical
pharmacology unit,the mean fluctuation was 31 ms in
118 male and female subjects
52 and 31±14 ms (range:
4–63 ms) for 82 male subjects (Patat, unpublished
data). Finally, the average maximum increase from
baseline observed postdose in placebo-treated subjects
was 17 ms over 8 hours postdose
52 and 14.0±12.7 ms
over 12 hours postdose (Patat, unpublished data).
Patients with cardiac disease show a greater sponta-
neous variation and a somewhat exaggerated QT
response to drug effect.
48
Based on these data in healthy subjects,it may be con-
cluded that individual changes of QTc of less than 40
ms reflect normal biological and methodological vari-
ability and are unlikely to indicate drug effects, that
individual changes between 40 and 60 ms are probably
beyond normal biological and methodological variabil-
ity and indicate possible proarrhythmogenic drug
effects,and that individual changes above 60 ms exceed
the normal biological and methodological variability,
and indicate proarrhythmogenic drug effects.
Current guidelines place emphasis on two types of flags:
raw QTc and delta values (change from baseline).There
is little agreement among the scientific community on
what constitutes a prolonged QTc interval.The Food and
Drug Administration (FDA) in the United States has not
issued any sort of formal guidance on the matter,but the
EMEA has issued a guidance document.
39 The EMEA
proposes that changes in QTc intervals between 30 and
60 ms are likely to represent a drug effect, and changes
greater than 60 ms “raise clear concerns about the poten-
tial risk.”Also,if the raw QTc interval is greater than 450
or 470 ms for males or females,respectively,then this too
is evidence of prolonged QTc interval, even if only val-
ues above 500 ms “raise clear concerns about the poten-
tial risk.” Morganroth et al
51 and Garson
53 recommend
that a change in QTc interval greater than 75 ms or a
maximal QTc interval of 500 ms is clinically abnormal.
They consider the upper limit of normal as 440 ms.Using
the observed placebo variability, Pratt et al
48 calculated
that an increase in QTc interval >35 ms while receiving
drug therapy is likely to represent a drug effect at the
95% confidence interval.
Finally, in addition to a prolongation of the QTc inter-
val, a change in T-wave morphology and occurrence of
a U wave constitute important warning signs of similar
significance to a QTc prolongation.
When interpreting QTc values,various factors influenc-
ing QT interval prolongation should be taken into
account:prolonged baseline QT interval (long QT syn-
drome), gender, bradycardia, cardiac or other diseases
(myocardial ischemia, heart failure, stroke, or cirrhosis
of the liver),and electrolyte disturbances (hypokalemia,
hypomagnesemia,or hypocalcemia).
An additional QT parameter was proposed by the
EMEA guidance,QT dispersion.QT dispersion (QTd)
is increasingly thought to be of importance. QTd is
defined as the difference between the shortest and the
longest QT interval in a set of 6 to 12 ECG leads and,
as such, describes the interlead QT variability. QTd
reflects regional dispersion or inhomogeneity of ven-
tricular repolarization. Since dispersion of ventricular
repolarization is associated with enhanced vulnerabil-
ity to ventricular arrhythmias, QTd was proposed as a
simple predictor for the propensity of ventricular
arrhythmia.Normal values range from 40 to 60 ms for
a 12-lead ECG. Threshold values are individual
increases in QTd of more than 100% and an absolute
dispersion above 100 ms.
39 Measurement of QTd is the
most controversial recommendation, as it is a new
measure not readily available or in clinical use; its
prognostic value in cardiac disease still needs to be
established. Methodological issues still exist (number
of leads to be used,correction for heart rate,correction
for missing values) and there are large errors regard-
less of the method applied in QTd measurement: the
coefficient of variation (CV) ranges from 20% (with-
in-day) to 30% (between-day) compared with CV of
3% to 5% for QTc.
When studying an NCE with no preclinical findings
indicating QT prolongation,ECG data should be gen-
erated in at least 100 subjects in early phase 1 and/or 2
studies, paying particular attention to the dose–effect
relationship, steady state plasma levels, gender effect,
age effect, and metabolic capacity (if a metabolite is
involved). Drug–drug interactions with inhibitors or
inducers of the NCE’s metabolism also need to be con-
sidered to look for potential cardiac effects.
When studying an NCE with preclinical findings indi-
cating QT prolongation, more extensive investigation
is required.The early clinical testing should be per-
formed in at least 200 subjects.If QTc prolongation or
other ECG effects are observed in these early studies,
it is recommended that ECG measurements be made
in all patients included in the clinical development
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program. ECG should be recorded prior to drug
intake and at steady-state plasma levels of the drug
and/or its metabolite, and plasma potassium levels
should also be measured at the same time. Holter
monitoring should be considered to determine
whether QTc prolongation complicates into arrhyth-
mia and/or T-wave morphological changes. Phase 2
and/or 3 studies must include the likely at-risk groups,
eg, women, the elderly, patients of different pheno-
types, and patients with concomitant disease, such as
renal or hepatic impairment or cardiovascular disease
with and without diuretic treatment. ❑
El diseño y la interpretación de los resultados
de estudios realizados por primera vez en el
ser humano.
La administración por primera vez en el ser huma-
no de una nueva sustancia química (NSQ) consti-
tuye un paso crítico en el desarrollo de fármacos.
El objetivo primario de un estudio de este tipo es
la evaluación de la seguridad en el corto plazo y
de la tolerancia a dosis únicas y múltiples de la
NSQ en voluntarios sanos. Son objetivos secunda-
rios el obtener datos preliminares de la farmacoci-
nética y farmacodinámica utilizando sucedáneos o
marcadores biológicos tanto para los efectos
beneficiosos como para los efectos adversos de la
sustancia. La interpretación de la seguridad de los
datos debe ser cuidadosa y basarse principalmen-
te en comparaciones con placebo. Debe prestarse
especial atención a la evaluación de los efectos
adversos, las enzimas hepáticas y la repolarización
cardíaca. Los estudios realizados por primera vez
en el hombre, bien diseñados, deben determinar
la seguridad de la NSQ en seres humanos y prede-
cir el rango de dosis en que puede ser empleada,
para llevar a cabo futuros ensayos clínicos con
seguridad y precisión en alguna población defini-
da de pacientes, de acuerdo con datos confiables
de dosis (dosis máxima tolerada), de farmacodiná-
mica (dosis activa mínima, duración de la acción y
régimen de dosificación) y de farmacocinética
(régimen de dosificación).Conception et interpré-
tation des résultats 
Conception et interpretation des résultats 
des études de première administration 
à l’homme 
La première administration à l’homme d’une enti-
té chimique nouvelle (ECN) représente une étape
critique dans le développement d’une molécule.
L’objectif principal d’une telle étude est d’évaluer
la sécurité et la tolérance à court terme après
administration de doses unique et multiples d’une
ECN chez des volontaires sains. Les objectifs
secondaires sont d’obtenir des données prélimi-
naires pharmacocinétiques et pharmacodyna-
miques sur les effets tant bénéfiques qu’indési-
rables de la molécule en utilisant des substituts ou
des marqueurs biologiques. L’interprétation des
données de sécurité d’emploi doit être prudente
et basée principalement sur des comparaisons
avec le placebo. L’évaluation des effets indési-
rables, les enzymes hépatiques et la repolarisation
cardiaque doivent faire l’objet d’un intérêt parti-
culier. Des études de première administration
chez l’homme bien conduites doivent déterminer
la sécurité d’emploi d’une ECN chez l’homme et
prévoir la fourchette de dose utilisable afin d’ef-
fectuer ultérieurement avec précision et sans
risque chez une population cible des études cli-
niques basées sur la sécurité (dose maximale tolé-
rée), la pharmacodynamique (dose minimale acti-
ve, durée d’action, schéma posologique) et la
pharmacocinétique (schéma posologique).
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